NASDAQ:BLU BELLUS Health (BLU) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free BLU Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.74▼$14.7550-Day Range$14.42▼$14.7552-Week Range$6.38▼$14.76Volume3.45 million shsAverage Volume3.08 million shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/APrice Target$14.75 Stock AnalysisStock Analysis Get BELLUS Health alerts: Email Address BELLUS Health MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside0.1% Upside$14.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.97) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.10 out of 5 starsMedical Sector927th out of 938 stocksBiotechnology Industry27th out of 28 stocks 1.1 Analyst's Opinion Consensus RatingBELLUS Health has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.75, BELLUS Health has a forecasted upside of 0.1% from its current price of $14.74.Amount of Analyst CoverageBELLUS Health has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BLU. Previous Next 0.0 Dividend Strength Dividend YieldBELLUS Health does not currently pay a dividend.Dividend GrowthBELLUS Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLU. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added BELLUS Health to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BELLUS Health insiders have not sold or bought any company stock.Percentage Held by Insiders24.17% of the stock of BELLUS Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.37% of the stock of BELLUS Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BELLUS Health are expected to decrease in the coming year, from ($0.97) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BELLUS Health is -20.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BELLUS Health is -20.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBELLUS Health has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About BELLUS Health Stock (NASDAQ:BLU)BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Read More Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here BLU Stock News HeadlinesMarch 21, 2024 | msn.comDeal reached between Dignity Health, Arizona Blue Cross Blue ShieldMarch 4, 2024 | msn.comThe effects of 'blue light' on human health are still unclear, says panelMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJanuary 4, 2024 | msn.comGlowing blue waves off Orange County coast make for thrilling start to New YearDecember 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Bluebird Bio (BLUE), United Therapeutics (UTHR)September 21, 2023 | forbes.comCBD Dosage: How Much Should You Take?June 28, 2023 | fool.comBellus Health (NASDAQ: BLU)June 27, 2023 | msn.comThese Canadian Biotech Stocks Are Quietly Changing the Face of HealthcareMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.June 25, 2023 | finance.yahoo.comBLU.TO - BELLUS Health Inc.June 17, 2023 | markets.businessinsider.comBTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)May 10, 2023 | ca.finance.yahoo.comTSX Stocks in the Healthcare Industry: Which Ones Are Worth Your Money?May 10, 2023 | finance.yahoo.comShould You Buy Bellus Health (BLU) After Golden Cross?May 2, 2023 | theglobeandmail.comClosing Bell: Bellus Health Inc up on Tuesday (BLU)April 26, 2023 | theglobeandmail.comBELLUS Health: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (BLU)April 26, 2023 | finance.yahoo.comBELLUS Health Announces Meeting UpdatesApril 21, 2023 | benzinga.comMoore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law FirmApril 19, 2023 | finance.yahoo.comBellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSKApril 19, 2023 | theglobeandmail.comGSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini familyApril 19, 2023 | reuters.comGSK bets $2 bln on Bellus cough drug to soothe pipeline fearsApril 18, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)April 18, 2023 | theglobeandmail.comGSK signs deal to buy Canadian drug developer Bellus Health for US$2 billionApril 18, 2023 | finance.yahoo.comBellus Health Soars 99% As GSK Joins Buyout Bonanza With $2 Billion DealApril 18, 2023 | cnbc.comStocks making the biggest moves midday: Southwest Airlines, Goldman Sachs, Bellus Health and moreApril 18, 2023 | bizjournals.comGSK to buy Canadian biopharm firm Bellus Health for $2 billionApril 18, 2023 | finance.yahoo.comBellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion DealApril 18, 2023 | finance.yahoo.comWhy BELLUS Health Stock Is Rocketing Higher TodaySee More Headlines Receive BLU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BLU CUSIPN/A CIK1259942 Webwww.bellushealth.com Phone(450) 680-4500Fax45-0680-4501Employees74Year FoundedN/APrice Target and Rating Average Stock Price Target$14.75 High Stock Price Target$14.75 Low Stock Price Target$14.75 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,080,000.00 Net Margins-578,586.63% Pretax Margin-578,226.56% Return on Equity-24.27% Return on Assets-23.14% Debt Debt-to-Equity RatioN/A Current Ratio33.42 Quick Ratio33.42 Sales & Book Value Annual Sales$15,000.00 Price / Sales124,613.93 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book4.77Miscellaneous Outstanding Shares126,812,000Free Float96,162,000Market Cap$1.87 billion OptionableNot Optionable Beta0.19 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Roberto Francesco Bellini (Age 43)Pres, CEO & Director Comp: $790.35kMr. Ramzi Benamar (Age 50)Chief Financial Officer Comp: $650.48kDr. Andreas Orfanos FFPM (Age 64)M.B.B.Ch, MBA, Chief Operating Officer Comp: $417.58kDr. Denis Garceau Ph.D. (Age 66)Chief Scientific Officer Comp: $496.56kDr. Catherine M. Bonuccelli M.D. (Age 65)Chief Medical Officer Comp: $741.66kMr. Daniel MatthewsDirector of Investor Relations & CommunicationsMr. Tony Matzouranis (Age 50)Chief Bus. Officer Mr. Sebastien Roy (Age 47)Corp. Sec. More ExecutivesKey CompetitorsSoleno TherapeuticsNASDAQ:SLNOIcosavaxNASDAQ:ICVXGracell BiotechnologiesNASDAQ:GRCLFate TherapeuticsNASDAQ:FATEVoyager TherapeuticsNASDAQ:VYGRView All Competitors BLU Stock Analysis - Frequently Asked Questions Should I buy or sell BELLUS Health stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLU shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLU, but not buy additional shares or sell existing shares. View BLU analyst ratings or view top-rated stocks. What is BELLUS Health's stock price target for 2024? 4 analysts have issued twelve-month price objectives for BELLUS Health's stock. Their BLU share price targets range from $14.75 to $14.75. On average, they predict the company's stock price to reach $14.75 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View analysts price targets for BLU or view top-rated stocks among Wall Street analysts. How were BELLUS Health's earnings last quarter? BELLUS Health Inc. (NASDAQ:BLU) issued its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%. What other stocks do shareholders of BELLUS Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST). This page (NASDAQ:BLU) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BELLUS Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.